
  
    
      
        
        Like_IN SARS_NNP ,_, Ebola_NNP ,_, and_CC other_JJ emerging_VBG infectious_JJ diseases_NNS ,_, antibiotic_JJ resistance_NN in_IN
        bacteria_NNS may_MD have_VB a_DT zoonotic_JJ origin_NN [_NN 1_CD ]_NN ._. Evidence_NN suggests_VBZ that_IN antibiotic_JJ use_NN in_IN
        agriculture_NN has_VBZ contributed_VBN to_TO antibiotic_JJ resistance_NN in_IN the_DT pathogenic_JJ bacteria_NNS of_IN humans_NNS ,_,
        but_CC the_DT chain_NN from_IN cause_NN to_TO effect_VB is_VBZ long_JJ and_CC complicated_VBN ._.
        Antibiotic_NNP use_NN clearly_RB selects_VBZ for_IN antibiotic_JJ resistance_NN ,_, but_CC how_WRB far_RB do_VBP these_DT effects_NNS
        extend_VBP beyond_IN the_DT population_NN where_WRB antibiotics_NNS are_VBP used_VBN ?_. Antibiotics_NNP and_CC
        antibiotic-resistant_JJ bacteria_NNS (_( ARB_NNP )_) are_VBP found_VBN in_IN the_DT air_NN and_CC soil_NN around_IN farms_NNS ,_, in_IN surface_NN
        and_CC ground_NN water_NN ,_, in_IN wild_JJ animal_NN populations_NNS ,_, and_CC on_IN retail_JJ meat_NN and_CC poultry_NN [_NN 2_CD –_NN 9_CD ]_NN ._. ARB_NNP are_VBP
        carried_VBN into_IN the_DT kitchen_NN on_IN contaminated_JJ meat_NN and_CC poultry_NN ,_, where_WRB other_JJ foods_NNS are_VBP
        cross-contaminated_JJ because_IN of_IN common_JJ unsafe_JJ handling_NN practices_NNS [_NN 10_CD ,_, 11_CD ]_NN ._. Following_VBG
        ingestion_NN ,_, bacteria_NNS occasionally_RB survive_VBP the_DT formidable_JJ but_CC imperfect_JJ gastric_JJ barrier_NN ,_, and_CC
        colonize_NN the_DT gut_NN [_NN 12_CD ]_NN ._.
        Patterns_NNS of_IN colonization_NN (_( asymptomatic_JJ carriage_NN )_) and_CC infection_NN (_( symptomatic_JJ carriage_NN )_) in_IN
        human_JJ populations_NNS provide_VBP additional_JJ evidence_NN that_IN ARB_NNP occasionally_RB move_NN from_IN animals_NNS to_TO
        humans_NNS [_NN 13_CD ,_, 14_CD ]_NN ._. The_DT strongest_JJS evidence_NN comes_VBZ from_IN the_DT history_NN of_IN the_DT use_NN of_IN antibiotics_NNS for_IN
        growth_NN promotion_NN in_IN Europe_NNP ._. After_IN first_JJ Denmark_NNP and_CC then_RB the_DT European_NNP Union_NNP banned_VBD the_DT use_NN
        of_IN antibiotics_NNS for_IN growth_NN promotion_NN ,_, prevalence_NN of_IN resistant_JJ bacteria_NNS declined_VBD in_IN farm_NN
        animals_NNS ,_, in_IN retail_JJ meat_NN and_CC poultry_NN ,_, and_CC within_IN the_DT general_JJ human_JJ population_NN [_NN 8_CD ,_, 15_CD ]_NN ._.
        Despite_IN the_DT evidence_NN linking_VBG bacterial_JJ antibiotic_JJ resistance_NN on_IN farms_NNS to_TO resistance_NN in_IN
        humans_NNS ,_, the_DT impact_NN of_IN agricultural_JJ antibiotic_JJ use_NN remains_VBZ controversial_JJ [_NN 16_CD –_NN 19_CD ]_NN and_CC poorly_RB
        quantified_VBN ._. This_DT is_VBZ partly_RB because_IN of_IN the_DT complex_NN of_IN population-level_JJ processes_VBZ underlying_VBG
        the_DT between-species_JJ (_(“ heterospecific_JJ” )_) and_CC within-species_JJ ,_, host-to-host_JJ (_(“ horizontal_NN” )_)
        spread_NN of_IN ARB_NNP ._. To_TO emerge_VB as_IN human_JJ pathogens_NNS ,_, new_JJ strains_NNS of_IN ARB_NNP must_MD (_( 1_LS )_) evolve_VB ,_,
        originating_VBG from_IN mutations_NNS or_CC gene_NN transfer_NN ;_: (_( 2_LS )_) spread_NN ,_, usually_RB horizontally_RB among_IN humans_NNS
        or_CC animals_NNS ,_, but_CC occasionally_RB heterospecifically_RB ;_: and_CC (_( 3_LS )_) cause_VB disease_NN ._.
        All_DT three_CD of_IN these_DT steps_NNS are_VBP complex_JJ and_CC imperfectly_RB understood_VBN ._. The_DT emergence_NN of_IN a_DT new_JJ
        type_NN of_IN resistance_NN is_VBZ a_DT highly_RB random_JJ event_NN ,_, which_WDT ca_MD n't_RB be_VB predicted_VBN accurately_RB ,_, and_CC may_MD
        involve_VB multiple_JJ steps_NNS that_WDT preclude_VB perfect_JJ understanding_NN even_RB after_IN the_DT fact_NN ._. Spread_NNP is_VBZ
        equally_RB complicated_VBN and_CC may_MD obscure_VB the_DT origins_NNS of_IN resistance_NN ._. In_IN some_DT cases_NNS ,_, emergence_NN of_IN
        resistance_NN in_IN one_CD bacterial_JJ species_NNS is_VBZ a_DT consequence_NN of_IN the_DT emergence_NN and_CC spread_NN in_IN another_DT
        species_NNS ,_, followed_VBN by_IN the_DT transfer_NN of_IN resistance_NN genes_NNS from_IN one_CD bacterial_JJ species_NNS to_TO
        another_DT ._. Because_IN of_IN the_DT underlying_VBG complexity_NN ,_, mathematical_JJ models_NNS are_VBP necessary_JJ to_TO develop_VB
        theory—a_NN qualitative_JJ understanding_NN of_IN the_DT underlying_VBG epidemiological_JJ processes_VBZ [_NN 20_CD –_NN 25_CD ]_NN ._.
        Theory_NNP helps_VBZ researchers_NNS organize_VB facts_NNS ,_, identify_VB missing_VBG information_NN ,_, design_NN surveillance_NN ,_,
        and_CC analyze_VB data_NNS [_NN 26_CD ]_NN ._.
      
      
        Horizontal_NNP Transmission_NNP
        Theory_NNP clearly_RB shows_VBZ that_IN the_DT impact_NN of_IN agricultural_JJ antibiotic_JJ use_NN depends_VBZ on_IN whether_IN
        resistant_JJ bacteria_NNS have_VBP high_JJ ,_, low_JJ ,_, or_CC intermediate_JJ horizontal_NN transmission_NN rates_NNS in_IN human_JJ
        populations_NNS [_NN 23_CD ,_, 24_CD ]_NN ._. The_DT rate_NN of_IN horizontal_NN transmission_NN among_IN humans_NNS is_VBZ determined_VBN by_IN the_DT
        underlying_VBG biology_NN of_IN the_DT pathogen_NN ,_, medical_JJ antibiotic_JJ use_NN ,_, and_CC hospital_NN infection_NN control_NN ,_,
        but_CC not_RB by_IN agricultural_JJ antibiotic_JJ use_NN [_NN 22_CD ]_NN ._. On_IN the_DT other_JJ hand_NN ,_, a_DT farm_NN where_WRB multiple_JJ
        antibiotics_NNS are_VBP used_VBN routinely_RB ,_, universally_RB ,_, and_CC in_IN low_JJ quantities_NNS for_IN growth_NN promotion_NN is_VBZ
        likely_JJ to_TO be_VB an_DT excellent_JJ environment_NN for_IN the_DT evolution_NN of_IN multiple_JJ resistance_NN factors_NNS ,_,
        including_VBG some_DT variants_NNS that_WDT might_MD never_RB have_VB evolved_VBN in_IN humans_NNS ._. Thus_RB ,_, even_RB very_RB rare_JJ
        transmission_NN resulting_VBG from_IN agricultural_JJ antibiotics_NNS may_MD have_VB a_DT medical_JJ impact_NN by_IN
        introducing_VBG new_JJ resistant_JJ variants_NNS to_TO the_DT human_JJ population_NN ._. The_DT epidemiology_NN of_IN spread_NN in_IN
        the_DT human_JJ population_NN dictates_VBZ how_WRB the_DT impact_NN of_IN agricultural_JJ antibiotic_JJ use_NN should_MD be_VB
        assessed_VBN ._.
        Zoonotic_NNP pathogens_NNS ,_, such_JJ as_IN 
        Campylobacter_NNP and_CC 
        Salmonella_NNP ,_, are_VBP generally_RB regarded_VBN as_IN having_VBG low_JJ horizontal_NN
        transmission_NN rates_NNS in_IN human_JJ populations_NNS ._. While_IN resistance_NN in_IN zoonotic_JJ infections_NNS should_MD be_VB
        directly_RB attributable_JJ to_TO resistance_NN in_IN the_DT zoonotic_JJ reservoir_NN ,_, the_DT impact_NN of_IN agricultural_JJ
        antibiotic_JJ use_NN remains_VBZ controversial_JJ [_NN 18_CD ,_, 27_CD –_NN 29_CD ]_NN ._. Zoonotic_NNP species_NNS could_MD acquire_VB resistance_NN
        genes_NNS from_IN human_JJ commensal_NN bacteria_NNS during_IN the_DT infection_NN process_NN ,_, but_CC this_DT hypothesis_NNS is_VBZ
        difficult_JJ to_TO test_VB ._.
        For_IN pathogens_NNS with_IN high_JJ horizontal_NN transmission_NN rates_NNS ,_, resistant_JJ bacteria_NNS will_MD spread_VB
        rapidly_RB once_RB they_PRP have_VBP emerged_VBN ,_, and_CC prevalence_NN will_MD be_VB maintained_VBN at_IN a_DT steady_JJ state_NN by_IN
        horizontal_NN transmission_NN ._. Thus_RB ,_, the_DT impact_NN of_IN subsequent_JJ heterospecific_JJ transmission_NN is_VBZ
        limited_VBN (_( Figure_NN 1_LS )_) ._. Nevertheless_RB ,_, one_CD or_CC two_CD heterospecific_JJ transmission_NN events_NNS could_MD be_VB
        sufficient_JJ to_TO cause_VB the_DT appearance_NN of_IN a_DT highly_RB successful_JJ ARB_NNP genotype_NN in_IN humans_NNS ,_, affecting_VBG
        the_DT timing_NN ,_, nature_NN ,_, and_CC extent_NN of_IN spread_NN within_IN the_DT human_JJ population_NN [_NN 22_CD ]_NN ._. Not_RB only_RB are_VBP
        such_JJ events_NNS difficult_JJ to_TO trace_VB ,_, but_CC their_PRP$ impact_NN is_VBZ impossible_JJ to_TO measure_VB ,_, since_IN there_EX is_VBZ
        no_DT way_NN to_TO know_VB what_WP type_NN of_IN resistance_NN would_MD have_VB appeared_VBN and_CC with_IN what_WP temporal_JJ pattern_NN ,_,
        if_IN transfers_NNS from_IN animals_NNS had_VBD been_VBN prevented_VBN ._.
        The_DT case_NN where_WRB horizontal_NN human_JJ transmission_NN rates_NNS are_VBP intermediate_JJ is_VBZ particularly_RB
        interesting_JJ ._. If_IN each_DT case_NN in_IN a_DT population_NN generates_VBZ approximately_RB one_CD new_JJ case_NN (_( a_DT situation_NN
        we_PRP call_VBP “ quasi-epidemic_JJ” transmission_NN )_) ,_, each_DT instance_NN of_IN heterospecific_JJ transmission_NN will_MD
        initiate_VB a_DT long_JJ chain_NN of_IN horizontal_NN transmission_NN that_IN eventually_RB burns_VBZ out_RP ._. Quasi-epidemic_NNP
        transmission_NN can_MD amplify_VB a_DT relatively_RB low_JJ amount_NN of_IN heterospecific_JJ transmission_NN and_CC
        substantially_RB increase_VB prevalence_NN [_NN 23_CD –_NN 25_CD ]_NN ._. The_DT effect_NN is_VBZ sustained_VBN as_RB long_RB as_IN
        heterospecific_JJ transmission_NN continues_VBZ ._. A_DT corollary_JJ is_VBZ that_IN banning_VBG agricultural_JJ antibiotic_JJ
        use_NN would_MD have_VB maximal_NN benefits_NNS if_IN horizontal_NN transmission_NN is_VBZ quasi-epidemic_JJ [_NN 24_CD ]_NN ._.
        Moreover_RB ,_, the_DT effects_NNS are_VBP most_RBS difficult_JJ to_TO estimate_VB because_IN both_DT heterospecific_JJ and_CC
        horizontal_NN transmission_NN must_MD be_VB accounted_VBN for_IN ._.
        These_DT principles_NNS apply_VBP to_TO bacteria_NNS associated_VBN with_IN outpatient_NN antibiotic_JJ use_NN and_CC
        community-acquired_JJ infections_NNS as_RB well_RB as_IN those_DT that_WDT are_VBP primarily_RB hospital-acquired_JJ ._.
        Although_IN quasi-epidemic_JJ transmission_NN would_MD seem_VB to_TO be_VB a_DT special_JJ case_NN ,_, it_PRP may_MD in_IN fact_NN be_VBP the_DT
        rule_NN for_IN many_JJ hospital-acquired_JJ bacteria_NNS because_IN it_PRP is_VBZ the_DT natural_JJ endpoint_NN of_IN the_DT
        interplay_NN between_IN economics_NNS and_CC ecology_NN [_NN 30_CD ]_NN ._. By_IN spending_NN money_NN on_IN hospital_NN infection_NN
        control_NN ,_, hospital_NN administrators_NNS can_MD reduce_VB nosocomial_NN transmission_NN rates_NNS for_IN resistant_JJ
        bacteria_NNS ._. For_IN example_NN ,_, hospitals_NNS may_MD screen_VB and_CC isolate_VB patients_NNS who_WP are_VBP likely_JJ to_TO be_VB
        carriers_NNS (_( i_NNP ._. e_SYM ._. ,_, active_JJ surveillance_NN )_) and_CC implement_VB infection-control_JJ measures_NNS ,_, but_CC this_DT
        comes_VBZ at_IN the_DT cost_NN of_IN isolating_VBG patients_NNS [_NN 31_CD ]_NN ._. Total_JJ costs_NNS are_VBP minimized_VBN by_IN spending_VBG just_RB
        enough_RB to_TO eliminate_VB (_( or_CC nearly_RB eliminate_VB )_) the_DT pathogen_NN ;_: thus_RB ,_, quasi-epidemic_JJ transmission_NN
        is_VBZ the_DT economic_JJ optimum_JJ [_NN 30_CD ]_NN ._.
      
      
        The_DT Community_NNP as_IN a_DT Reservoir_NNP for_IN Resistance_NNP
        Horizontal_NNP transmission_NN is_VBZ further_RBR complicated_VBN by_IN population_NN structure_NN ,_, such_JJ as_IN the_DT
        movement_NN of_IN humans_NNS through_IN hospitals_NNS and_CC long-term_JJ care_NN facilities_NNS ._. Medical_NNP antibiotic_JJ use_NN
        and_CC horizontal_NN transmission_NN rates_NNS are_VBP high_JJ in_IN hospitals_NNS ,_, but_CC this_DT is_VBZ counterbalanced_VBN by_IN
        short_JJ hospital_NN stays_NNS ._. An_DT emerging_VBG view_NN for_IN hospital-acquired_JJ bacterial_JJ infections_NNS is_VBZ that_IN
        persistent_JJ asymptomatic_JJ carriage_NN plays_VBZ a_DT key_JJ role_NN in_IN the_DT epidemic_NN of_IN resistance_NN ._. ARB_NNP can_MD
        asymptomatically_RB colonize_NN a_DT person_NN for_IN years_NNS :_: even_RB if_IN the_DT number_NN of_IN other_JJ people_NNS infected_VBN
        during_IN a_DT single_JJ hospital_NN visit_NN is_VBZ less_JJR than_IN one_CD ,_, this_DT number_NN will_MD exceed_VB one_CD when_WRB summed_VBD
        over_IN several_JJ hospital_NN visits_NNS [_NN 25_CD ,_, 32_CD ,_, 33_CD ]_NN ._. Thus_RB ,_, the_DT ecological_JJ reservoir_NN of_IN resistance_NN in_IN
        the_DT community_NN plays_VBZ an_DT important_JJ role_NN in_IN the_DT increasing_VBG frequency_NN of_IN resistance_NN in_IN
        hospital-acquired_JJ infections_NNS ._.
        Short_JJ hospital_NN visits_NNS and_CC long_JJ persistence_NN times_NNS of_IN ARB_NNP in_IN people_NNS guarantee_VBP that_IN some_DT of_IN
        the_DT costs_NNS associated_VBN with_IN failed_JJ infection_NN control_NN are_VBP passed_VBN on_IN to_TO other_JJ hospitals—new_NN
        carriers_NNS are_VBP frequently_RB discharged_VBN from_IN one_CD hospital_NN only_RB to_TO be_VB admitted_VBN to_TO another_DT
        hospital_NN later_RB [_NN 30_CD ]_NN ._. Thus_RB ,_, the_DT harm_NN done_VBN by_IN these_DT ARB_NNP is_VBZ borne_VBN by_IN the_DT whole_JJ human_JJ
        population_NN ,_, particularly_RB all_DT of_IN the_DT health-care_NN institutions_NNS that_WDT serve_VBP a_DT single_JJ catchment_NN
        population_NN ._. In_IN economic_JJ terms_NNS ,_, the_DT damage_NN caused_VBN by_IN the_DT carriage_NN of_IN ARB_NNP is_VBZ a_DT kind_NN of_IN
        pollution_NN ._.
        By_IN comparing_VBG the_DT total_JJ number_NN of_IN new_JJ carriers_NNS generated_VBN in_IN the_DT community_NN ,_, the_DT impacts_NNS of_IN
        agricultural_JJ antibiotic_JJ use_NN on_IN hospitals_NNS can_MD be_VB compared_VBN directly_RB to_TO the_DT impact_NN hospitals_NNS
        have_VBP on_IN each_DT other_JJ (_( Figure_NN 2_LS )_) ._. The_DT rate_NN of_IN heterospecific_JJ transmission_NN is_VBZ intrinsically_RB
        difficult_JJ to_TO measure_VB directly_RB because_IN the_DT risk_NN of_IN exposure_NN and_CC colonization_NN per_IN meal_NN is_VBZ
        very_RB small_JJ ._. Nevertheless_RB ,_, agricultural_JJ antibiotic_JJ use_NN may_MD generate_VB as_IN many_JJ carriers_NNS as_IN
        hospitals_NNS for_IN the_DT simple_JJ reason_NN that_IN the_DT population_NN experiences_NNS many_JJ more_JJR meals_NNS than_IN
        hospital_NN discharges_NNS [_NN 34_CD ]_NN ._. When_WRB agricultural_JJ and_CC nosocomial_NN transmission_NN are_VBP equally_RB rare_JJ in_IN
        the_DT population_NN ,_, the_DT latter_NN will_MD be_VB much_RB easier_JJR to_TO identify_VB and_CC quantify_VB ._.
      
      
        A_DT Natural_NNP Experiment_NNP :_: Glycopeptides_NNP and_CC Vancomycin-_NNP Resistant_NNP Enterococci_NNP
        Is_VBZ the_DT impact_NN of_IN agricultural_JJ antibiotic_JJ use_NN on_IN the_DT emergence_NN and_CC spread_NN of_IN ARB_NNP in_IN
        humans_NNS large_JJ or_CC small_JJ relative_NN to_TO medical_JJ antibiotic_JJ use_NN ?_. Put_VB another_DT way_NN ,_, are_VBP farms_NNS or_CC
        hospitals_NNS bigger_JJR polluters_NNS ?_. A_DT large-scale_JJ natural_JJ experiment_NN was_VBD conducted_VBN in_IN the_DT United_NNP
        States_NNPS and_CC several_JJ European_JJ countries_NNS when_WRB each_DT adopted_VBN different_JJ policies_NNS on_IN glycopeptide_NN
        use_NN in_IN animals_NNS (_( avoparcin_NN )_) and_CC humans_NNS (_( vancomycin_NN )_) [_NN 16_CD ,_, 17_CD ,_, 35_CD –_NN 37_CD ]_NN ._. Many_JJ European_JJ countries_NNS
        approved_VBD avoparcin_NN for_IN animal_NN growth_NN promotion_NN in_IN the_DT 1970_CD s_VBZ ,_, but_CC the_DT US_NNP did_VBD not_RB ._.
        In_IN the_DT early_JJ 1980_CD s_VBZ ,_, demand_NN for_IN vancomycin_NN in_IN US_NNP hospitals_NNS surged_VBD because_IN of_IN increasing_VBG
        aminoglycoside_NN resistance_NN among_IN enterococci_NN and_CC methicillin_NN resistance_NN in_IN 
        Staphylococcus_NNP aureus_NN ._. Physicians_NNPS in_IN US_NNP hospitals_NNS also_RB used_VBN
        oral_JJ vancomycin_NN for_IN some_DT 
        Clostridium_NNP difficile_NN infections_NNS [_NN 37_CD –_NN 39_CD ]_NN ._. In_IN the_DT late_JJ 1980_CD s_VBZ and_CC
        early_JJ 1990_CD s_VBZ ,_, vancomycin-resistant_JJ enterococci_NN (_( VRE_NNP )_) emerged_VBD and_CC spread_NN through_IN US_NNP
        health-care_NN systems_NNS ._. In_IN Europe_NNP ,_, hospitals_NNS used_VBD less_JJR vancomycin_NN because_IN most_JJS enterococci_NN
        were_VBD sensitive_JJ to_TO aminoglycosides_NNS ,_, and_CC oral_JJ vancomycin_NN was_VBD seldom_RB used_VBN ._. VRE_NNP still_RB emerged_VBD
        and_CC spread_NN through_IN European_JJ hospitals_NNS ,_, but_CC the_DT problem_NN has_VBZ been_VBN less_RBR severe_JJ than_IN in_IN the_DT US_NNP
        [_NN 40_CD ]_NN ._.
        A_DT different_JJ pattern_NN emerges_VBZ for_IN community_NN prevalence_NN of_IN VRE_NNP ._. VRE_NNP are_VBP rarely_RB found_VBN
        outside_IN of_IN hospitals_NNS in_IN the_DT US_NNP ,_, except_IN for_IN patients_NNS who_WP have_VBP a_DT prior_JJ history_NN of_IN
        hospitalization_NN ._. Community_NN prevalence_NN of_IN VRE_NNP in_IN the_DT US_NNP is_VBZ typically_RB less_JJR than_IN 1_CD %_NN ._. In_IN
        contrast_NN ,_, community_NN prevalence_NN of_IN VRE_NNP was_VBD estimated_VBN at_IN 2_CD %_NN –_NN 12_CD %_NN in_IN Europe_NNP during_IN the_DT late_JJ
        1990_CD s_VBZ ,_, including_VBG carriage_NN by_IN people_NNS with_IN no_DT history_NN of_IN hospitalization_NN [_NN 17_CD ,_, 41_CD –_NN 48_CD ]_NN ._. In_IN other_JJ
        words_NNS ,_, the_DT European_JJ community_NN reservoir_NN generated_VBN by_IN vancomycin_NN use_NN in_IN hospitals_NNS and_CC
        avoparcin_NN use_NN in_IN agriculture_NN was_VBD apparently_RB much_RB larger_JJR than_IN the_DT US_NNP community_NN reservoir_NN
        generated_VBN only_RB by_IN vancomycin_NN use_NN in_IN hospitals_NNS ._.
        The_DT prevalence_NN of_IN VRE_NNP in_IN the_DT community_NN declined_VBD after_IN the_DT EU_NNP banned_VBD avoparcin_NN [_NN 15_CD ]_NN ._.
        Thus_RB ,_, avoparcin_NN is_VBZ at_IN least_JJS partly_RB responsible_JJ for_IN the_DT reservoir_NN of_IN VRE_NNP in_IN the_DT European_JJ
        community_NN ,_, but_CC how_WRB much_JJ of_IN that_DT reservoir_NN came_VBD from_IN avoparcin_NN and_CC how_WRB much_RB came_VBD from_IN
        hospitals_NNS ?_. To_TO weigh_VB the_DT impact_NN ,_, we_PRP subtract_VB the_DT community_NN prevalence_NN of_IN VRE_NNP in_IN the_DT US_NNP
        (_( <_NN 1_CD %_NN )_) from_IN the_DT community_NN prevalence_NN of_IN VRE_NNP in_IN Europe_NNP (_( >_NN 2_CD %_NN )_) ._. The_DT remainder_NN (_( >_NN 1_CD %_NN )_) is_VBZ
        attributed_VBN to_TO avoparcin_NN ._. This_DT analysis_NN probably_RB underestimates_NNS the_DT real_JJ impact_NN because_IN
        vancomycin_NN was_VBD used_VBN less_JJR in_IN European_JJ than_IN in_IN US_NNP hospitals_NNS ._. Thus_RB ,_, avoparcin_NN use_NN in_IN Europe_NNP
        would_MD appear_VB to_TO be_VB responsible_JJ for_IN generating_VBG a_DT larger_JJR reservoir_NN of_IN VRE_NNP in_IN the_DT community_NN
        than_IN US_NNP hospitals_NNS ._. Put_VB another_DT way_NN ,_, the_DT impact_NN of_IN avoparcin_NN use_NN on_IN European_JJ hospitals_NNS was_VBD
        larger_JJR than_IN the_DT impact_NN of_IN US_NNP hospitals_NNS on_IN one_CD another_DT ._.
      
      
        Conclusion_NNP
        Despite_IN the_DT evidence_NN that_DT avoparcin_NN use_NN has_VBZ had_VBD a_DT large_JJ impact_NN on_IN the_DT emergence_NN and_CC
        spread_NN of_IN VRE_NNP by_IN increasing_VBG the_DT reservoir_NN of_IN VRE_NNP in_IN the_DT EU_NNP ,_, some_DT uncertainty_NN continues_VBZ to_TO
        surround_VBP the_DT clinical_JJ significance_NN of_IN VRE_NNP strains_NNS of_IN animal_NN origin_NN and_CC of_IN the_DT zoonotic_JJ
        origins_NNS of_IN resistance_NN in_IN general_NN ._. Bacterial_NNP strains_NNS circulating_VBG in_IN hospitalized_VBN populations_NNS
        may_MD be_VB genetically_RB distinct_JJ from_IN those_DT circulating_VBG in_IN the_DT general_JJ human_JJ population_NN
        [_NN 13_CD ,_, 17_CD ,_, 49_CD ]_NN ._. Thus_RB ,_, bacterial_JJ populations_NNS are_VBP some_DT combination_NN of_IN zoonotic_JJ ,_, quasi-epidemic_JJ ,_,
        and_CC epidemic_NN strains_NNS ._. The_DT complexity_NN of_IN bacterial_JJ population_NN biology_NN and_CC genetics_NNS makes_VBZ it_PRP
        practically_RB impossible_JJ to_TO trace_VB bacteria_NNS (_( or_CC resistance_NN factors_NNS )_) from_IN the_DT farm_NN to_TO the_DT
        hospital_NN ,_, or_CC to_TO directly_RB attribute_VBP some_DT fraction_NN of_IN new_JJ infections_NNS to_TO agricultural_JJ
        antibiotic_JJ use_NN ._. Asymptomatic_NNP carriage_NN of_IN resistance_NN factors_NNS by_IN nonfocal_NN commensal_NN bacteria_NNS
        adds_VBZ to_TO a_DT general_JJ risk_NN of_IN resistance_NN ,_, but_CC transfer_NN of_IN resistance_NN among_IN bacterial_JJ species_NNS is_VBZ
        unpredictable_JJ and_CC difficult_JJ to_TO quantify_VB ._. Until_IN more_JJR evidence_NN is_VBZ available_JJ ,_, it_PRP is_VBZ prudent_JJ
        and_CC reasonable_JJ to_TO consider_VB bacteria_NNS with_IN resistance_NN genes_NNS a_DT general_JJ threat_NN [_NN 50_CD –_NN 52_CD ]_NN ._.
        Some_DT part_NN of_IN the_DT controversy_NN over_IN agricultural_JJ antibiotic_JJ use_NN has_VBZ been_VBN a_DT disagreement_NN
        about_IN how_WRB to_TO weigh_VB evidence_NN and_CC make_VB decisions_NNS when_WRB the_DT underlying_VBG biological_JJ processes_NNS are_VBP
        complex_JJ ._. In_IN this_DT case_NN ,_, the_DT effects_NNS of_IN agricultural_JJ antibiotic_JJ use_NN on_IN human_JJ health_NN remain_VB
        uncertain_JJ ,_, despite_IN extensive_JJ investigation_NN ,_, and_CC the_DT effects_NNS may_MD be_VB unknowable_JJ ,_, unprovable_JJ ,_,
        or_CC immeasurable_JJ by_IN the_DT empirical_JJ standards_NNS of_IN experimental_JJ biology_NN ._. What_WP should_MD be_VB done_VBN
        when_WRB complexity_NN makes_VBZ an_DT important_JJ public-health_NN effect_NN intrinsically_RB difficult_JJ to_TO measure_VB ?_.
        What_WP is_VBZ an_DT appropriate_JJ “ null_NN hypothesis_NNS” or_CC its_PRP$ equivalent_NN ?_. Should_MD the_DT same_JJ standards_NNS of_IN
        proof_NN be_VB used_VBN in_IN science_NN and_CC science-based_JJ policy_NN ?_. Where_WRB should_MD the_DT burden_NN of_IN proof_NN
        fall_NN ?_.
        Scientific_JJ assessments_NNS for_IN policy_NN should_MD summarize_VB the_DT best_JJS state_NN of_IN the_DT science_NN ,_,
        recognizing_VBG that_IN the_DT burdens_NNS and_CC standards_NNS of_IN proof_NN are_VBP necessarily_RB softer_JJR because_IN of_IN the_DT
        uncertainty_NN that_WDT is_VBZ introduced_VBN by_IN biological_JJ complexity_NN ._. The_DT best_JJS decisions_NNS weigh_VBP the_DT
        evidence_NN in_IN light_NN of_IN the_DT inherent_JJ uncertainty_NN ._. The_DT EU_NNP banned_VBD the_DT use_NN of_IN antibiotics_NNS for_IN
        growth_NN promotion_NN ,_, based_VBN on_IN the_DT precautionary_JJ principle_NN ._. The_DT use_NN of_IN the_DT precautionary_JJ
        principle_NN was_VBD criticized_VBN by_IN some_DT as_IN unscientific_JJ in_IN this_DT context_NN ._. In_IN fact_NN ,_, the_DT intrinsic_JJ
        problem_NN of_IN knowability_NN ,_, posed_VBN by_IN the_DT biological_JJ complexity_NN of_IN the_DT problem_NN ,_, makes_VBZ the_DT use_NN of_IN
        precautionary_JJ decision_NN making_VBG particularly_RB suitable_JJ in_IN this_DT arena_NN ._. The_DT assumption_NN that_IN
        plausible_JJ dangers_NNS are_VBP negligible_JJ ,_, even_RB when_WRB it_PRP is_VBZ known_VBN that_IN such_JJ dangers_NNS are_VBP
        constitutively_RB very_RB difficult_JJ to_TO measure_VB ,_, may_MD be_VB more_RBR unscientific_JJ than_IN the_DT use_NN of_IN
        precaution_NN ._.
      
    
  
